BioRestorative announces notice of allowance by EPO for ThermoStem program

BioRestorative Therapies announced that the European Patent Office, EPO, has issued a notice of allowance for a patent application related to the Company's metabolic ThermoStem program. The notice of allowance was issued on February 6, 2023. Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose-derived stem cells. The therapeutic combination of scaffolds as a delivery system and brown adipose-derived stem cells provides the ability to deliver metabolically active cells. Certain companies that use encapsulation technology coupled with cells have shown promising clinical results treating type 1 diabetes in their Phase 1/2 clinical trials. "Our patent family for our ThermoStem program continues to grow as we receive additional patent grants in key markets," said Lance Alstodt, the Company's CEO. "We are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem developed by BioRestorative's scientists, enhances our ability to do so in European jurisdictions."